Dr Haumschild leads a discussion surrounding the latest advancements in treatment algorithms for myelodysplastic syndrome. The discussion centered on diverse treatment strategies for myelodysplastic ...
Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. We all know that MDS is a cancer of the ...
Dr. Shah was compensated by BMS for his participation. Photo Credit: Shutterstock As you age, feeling tired or short of breath may be dismissed as a part of getting older, but it’s important to talk ...
Dr. Inga Hofman Zhang from the University of Wisconsin School of Medicine provides an update on treating MDS in children. Dr. Naval Daver from MD Anderson Cancer Center talks about the relationship ...
Study findings provide new tools to assess treatment preferences when using hypomethylating agents in myelodysplastic syndromes (MDS). The study aimed to develop the TPMQ for clinicians (mTPMQ), ...
Please provide your email address to receive an email when new articles are posted on . Most patients with newly diagnosed high-risk myelodysplastic syndrome do not receive guideline-recommended ...
Social worker Marie Brewer talks about the challenges of supporting a loved one with myelodysplastic syndrome (MDS) and ways to find assistance and treatment options. Myelodysplastic syndromes (MDS) ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...
Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results published in Blood Neoplasia. The ...
t-MDS treatments boost remission with HMA combinations, yet overall survival still lags; experts await breakthrough therapies ...
For over a decade, the standard of care for high-risk MDS has remained a class of drugs called hypomethylating agents (HMAs).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results